Tango Therapeutics, Inc. (NASDAQ: TNGX) reported Q4 EPS of ($0.32), $0.05 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $5.43 million versus the consensus estimate of $8.62 million.

For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.